CliffBio
biologic

Anascorp

Centruroides (Scorpion) Immune F(ab')2 (Equine) Injection

Loss of exclusivityAugust 2023projected — 12-year biologic exclusivity estimate
CompanyRare Disease Therapeutics, Inc. (RDT)

Drug detail

Brand nameAnascorp
Active ingredientCentruroides (Scorpion) Immune F(ab')2 (Equine) Injection
Strength>/=150 LD50 NEUTRALIZING UNITS
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalAugust 2011
Marketing statusRx

More from Rare Disease Therapeutics, Inc. (RDT)

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Anascorp patent cliff — loss of exclusivity August 2023 | CliffBio